Teens Are Having Much Less Sex Than Their Parents Did at That Age
Adolescents may be thinking about sex all the time, but fewer teens are actually doing the deed. Since 1988, sex has dropped by 14 percent among teenage females (ages 15 to 19) and 22 percent among teenage males (ages 15 to 19). The latest study from the U.S. Centers for Disease Control and Prevention’s National Center for Health Statistics shows that 44 percent of female teenagers and 47 percent of male teenagers had experienced sexual intercourse at least once.
Related: The App-Selling Power of Kate Upton’s Cleavage
The good news? The majority of them used contraception. From 2011 to 2013, 79 percent of female teenagers and 84 percent of male teenagers used contraception the first time they had sexual intercourse. Condoms were the most widely used method of contraception among teenage girls, followed by withdrawal (60 percent) and the pill (54 percent). Use of the emergency “Plan B” or “morning after pill” came in fourth, reaching 22 percent in 2013, and up from 8 percent in 2002.
About 70 percent of 15- to 19-year-old females said their first sexual intercourse happened with a steady dating partner, compared to about 50 percent of 15- to 19-year-old males.
Could all that sex education be working? Are teenagers watching more porn? Do teens have more access to contraception because of Obamacare? Then again, it could be all those episodes of reality TV they’re watching. Last year CNN reported a study from the National Bureau of Economic Research that linked watching MTV’s 16 and Pregnant and Teen Mom to a 5.7 percent reduction in teen births in the U.S. The study found a correlation between higher rates of viewership in certain areas with a bigger decrease in teen births.
Related: Schools Gamble on Gut-Punch Anti-Drug Programs for Teens
Despite teen births being at an all-time low, the U.S. still leads other developed countries in teen pregnancy. (New Zealand comes in second, followed by England and Wales.) And if parents are worried their teens won’t ever get off their iPhones long enough to have sex, they can relax. Most teens, or two-thirds of adolescents, will have sex by the time they’re 19.
Chart of the Day: High Deductible Blues
The higher the deductible in your health insurance plan, the less happy you probably are with it. That’s according to a new report on employer-sponsored health insurance from the Kaiser Family Foundation and the Los Angeles Times.
Chart of the Day: Tax Cuts and the Missing Capex Boom
Despite the Republican tax overhaul, businesses aren’t significantly increasing their capital expenditures. “The federal government will have to borrow an added $1 trillion through 2027 to pay for the corporate tax breaks,” says Bloomberg’s Mark Whitehouse. “So far, it’s hard to see what the country is getting in return.”
Chart of the Day: 2019’s Lobbying Leaders
Roll Call reports that trade, infrastructure and health care issues including prescription drug prices “dominated the lobbying agendas of some of the biggest spenders on K Street early this year.” Here’s Roll Call’s look at the top lobbying spenders so far this year:
Can You Fix Social Security? A New Tool Lets You Try
The Congressional Budget Office released an interactive tool Wednesday that shows how some widely discussed policy changes would affect the long-run financial health of the Social Security system.
“This interactive tool allows the user to explore seven policy options that could be used to improve the Social Security program’s finances and delay the trust funds’ exhaustion,” CBO said. “Four options would reduce benefits, and three options would increase payroll taxes. The tool allows for any combination of those options. It also lets the user change implementation dates and choose whether to show scheduled or payable benefits. … The tool also shows the impact of the options on different groups of people.”
Click here to view the interactive tool on the CBO website.
Why Prescription Drug Prices Keep Rising – and 3 Ways to Bring Them Down
Prescription drug prices have been rising at a blistering rate over the last few decades. Between 1980 and 2016, overall spending on prescription drugs rose from about $12 billion to roughly $330 billion, while its share of total health care spending doubled, from 5% to 10%.
Although lawmakers have shown renewed interest in addressing the problem, with pharmaceutical CEOs testifying before the Senate Finance Committee in February and pharmacy benefit managers (PBMS) scheduled to do so this week, no comprehensive plan to halt the relentless increase in prices has been proposed, let alone agreed upon.
Robin Feldman, a professor at the University of California Hastings College of Law, takes a look at the drug pricing system in a new book, “Drugs, Money and Secret Handshakes: The Unstoppable Growth of Prescription Drug Prices.” In a recent conversation with Bloomberg’s Joe Nocera, Feldman said that one of the key drivers of rising prices is the ongoing effort of pharmaceutical companies to maintain control of the market.
Fearing competition from lower-cost generics, drugmakers began over the last 10 or 15 years to focus on innovations “outside of the lab,” Feldman said. These innovations include paying PBMs to reduce competition from generics; creating complex systems of rebates to PBMs, hospitals and doctors to maintain high prices; and gaming the patent system to extend monopoly pricing power.
Feldman’s research on the dynamics of the drug market led her to formulate three general solutions for the problem of ever-rising prices:
1) Transparency: The current system thrives on secret deals between drug companies and middlemen. Transparency “lets competitors figure out how to compete and it lets regulators see where the bad behaviors occur,” Feldman says.
2) Patent limitations: Drugmakers have become experts at extending patents on existing drugs, often by making minor modifications in formulation, dosage or delivery. Feldman says that 78% of drugs getting new patents are actually old drugs gaining another round of protection, and thus another round of production and pricing exclusivity. A “one-and-done” patent system would eliminate this increasingly common strategy.
3) Simplification: Feldman says that “complexity breeds opportunity,” and warns that the U.S. “drug price system is so complex that the gaming opportunities are endless.” While “ruthless simplification” of regulatory rules and approval systems could help eliminate some of those opportunities, Feldman says that the U.S. doesn’t seem to be moving in this direction.
Read the full interview at Bloomberg News.